(0.24%) 5 261.05 points
(0.18%) 39 833 points
(0.04%) 16 406 points
(2.05%) $83.02
(1.80%) $1.749
(1.23%) $2 239.90
(0.81%) $24.95
(1.32%) $921.70
(0.39%) $0.927
(0.80%) $10.86
(0.13%) $0.792
(0.20%) $92.62
Live Chart Being Loaded With Signals
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally...
Stats | |
---|---|
Today's Volume | 740 000 |
Average Volume | 292 244 |
Market Cap | 1.76B |
EPS | HKD0 ( 2023-08-25 ) |
Last Dividend | HKD0.0150 ( 2023-09-19 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 4.88 |
ATR14 | HKD0.0120 (1.03%) |
Volume Correlation
Dawnrays Pharmaceutical Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Dawnrays Pharmaceutical Correlation - Currency/Commodity
Dawnrays Pharmaceutical Financials
Annual | 2022 |
Revenue: | HKD1.28B |
Gross Profit: | HKD766.68M (60.01 %) |
EPS: | HKD0.240 |
Q2 | 2023 |
Revenue: | HKD649.92M |
Gross Profit: | HKD356.04M (54.78 %) |
EPS: | HKD0.170 |
Q4 | 2022 |
Revenue: | HKD654.20M |
Gross Profit: | HKD378.33M (57.83 %) |
EPS: | HKD0.120 |
Q2 | 2022 |
Revenue: | HKD623.48M |
Gross Profit: | HKD388.35M (62.29 %) |
EPS: | HKD0.110 |
Financial Reports:
No articles found.
Dawnrays Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0150 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0730 (N/A) |
HKD0.0150 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00750 | 2003-10-17 |
Last Dividend | HKD0.0150 | 2023-09-19 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | HKD0.998 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.5 | -- |
Div. Sustainability Score | 9.80 | |
Div.Growth Potential Score | 7.54 | |
Div. Directional Score | 8.67 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3958.HK | Ex Dividend Junior | 2023-05-23 | Annually | 0 | 0.00% | |
1795.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
0836.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
0006.HK | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
2368.HK | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% | |
1368.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
0436.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
6668.HK | Ex Dividend Knight | 2023-06-13 | Annually | 0 | 0.00% | |
1908.HK | Ex Dividend Junior | 2023-06-01 | Sporadic | 0 | 0.00% | |
0952.HK | No Dividend Player | 2023-09-14 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.339 | 1.500 | 3.22 | 4.82 | [0 - 0.5] |
returnOnAssetsTTM | 0.124 | 1.200 | 5.86 | 7.03 | [0 - 0.3] |
returnOnEquityTTM | 0.162 | 1.500 | 9.31 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.263 | -1.000 | 7.37 | -7.37 | [0 - 1] |
currentRatioTTM | 2.59 | 0.800 | 2.06 | 1.652 | [1 - 3] |
quickRatioTTM | 1.929 | 0.800 | 3.36 | 2.69 | [0.8 - 2.5] |
cashRatioTTM | 1.155 | 1.500 | 4.70 | 7.04 | [0.2 - 2] |
debtRatioTTM | 0.00940 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.238 | 2.00 | 9.92 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.103 | 2.00 | 9.95 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0119 | -1.500 | 9.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.563 | 1.000 | 3.95 | 3.95 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.289 | 1.000 | 6.22 | 6.22 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.68 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.367 | 0.800 | -0.889 | -0.711 | [0.5 - 2] |
Total Score | 9.80 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.67 | 1.000 | 9.73 | 0 | [1 - 100] |
returnOnEquityTTM | 0.162 | 2.50 | 9.55 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.103 | 2.00 | 9.97 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 8.15 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.238 | 2.00 | 9.92 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.263 | 1.500 | 7.37 | -7.37 | [0 - 1] |
pegRatioTTM | 0.636 | 1.500 | 9.09 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.274 | 1.000 | 5.65 | 0 | [0.1 - 0.5] |
Total Score | 7.54 |
Dawnrays Pharmaceutical
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators